Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

PHASE3CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

October 22, 2024

Study Completion Date

October 22, 2024

Conditions
Liver Fibrosis
Interventions
DRUG

Hydronidone capsules

After randomization, the experimental group were orally received hydronidone capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d,30 min before meals for 52 weeks.

DRUG

The placebo capsules

After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.

Trial Locations (44)

100020

Beijing Ditan Hospital Capital Medical University, Beijing

201620

Shanghai General Hospital,Shanghai Jiao Tong University, Shanghai

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei

Beijing You 'an Hospital, Capital Medical University, Beijing

Peking University First Hospital, Beijing

Tsinghua Changgeng Hospital, Beijing, Beijing

Chongqing Public Health Medical Treatment Center (Chongqing Infectious Disease Hospital), Chongqing

Chongqing Three Gorges Central Hospital, Chongqing

The First Affiliated Hospital of Chongqing Medical University, Chongqing

The First Affiliated Hospital of Fujian Medical University, Fujian

Xiamen Hospital of Traditional Chinese Medicine, Xiamen

Lanzhou university first hospital, Lanzhou

Shenzhen Third People's Hospital, Shenzhen

Guizhou Provincial People's Hospital, Guizhou

Affiliated Hospital of Zunyi Medical University, Zunyi

Hangzhou Xixi Hospital (Hangzhou Sixth People's Hospital), Hangzhou

The First Hospital of Hebei Medical University, Hebei

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

Henan Provincial People's Hospital, Henan

The First Affiliated Hospital of Xinxiang Medical College, Xinxiang

Zhengzhou Sixth People's Hospital, Zhengzhou

The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha

The Second Xiangya Hospital, Central South University, Changsha

Xiangya Hospital, Central South University, Changsha

The First Affiliated Hospital of University of South China, Yueyang

Jiangsu Provincial People's Hospital, Nanjing

The First Affiliated Hospital of SuZhou University, Suzhou

Taizhou People's Hospital, Taizhou

Wuxi Fifth People's Hospital, Wuxi

Affiliated Hospital of Xuzhou Medical College, Xuzhou

Zhenjiang Third People's Hospita, Zhenjiang

Nanchang Ninth Hospital (Nanchang Central Hospital), Nanchang

The First Affiliated Hospital of Nanchang University, Nanchang

First Hospital of Jilin University, Jilin

Second Hospital of Jilin University, Jilin

Yanbian University Affiliated Hospital, Yanbian

Huashan Hospital affiliated to Fudan University, Shanghai

Shanghai Jiao Tong University Affiliated Tongren Hospital, Shanghai

Shanghai Public Health Clinical Center, Shanghai

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai

West China Hospital of Sichuan University, Chengdu

Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou

Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo

All Listed Sponsors
lead

Beijing Continent Pharmaceutical Co, Ltd.

INDUSTRY

NCT05115942 - Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. | Biotech Hunter | Biotech Hunter